Squeeze Report has completed a short report for (NASDAQ: GNPX) Genprex, Inc. and concluded a Breakout is about to happen due to the key findings of the report.
Key Findings of the report;
Reviewing the trend for the past 20 trading days there is a potential Breakout about to happen because the past five days have shown an increase in short volume with very little cover volume. Prior to this there was a sell off which caused the price to fall but the decreasing cover volume and increasing short volume shows a rebound is about to happen. This is a sure sign of our Breakout trend indicator.
Five Day Short Analysis
Five Day trading Totals | |
---|---|
Total Shorted Volume | 6,854 |
Total Actual Volume | 158,094 |
Total Volume Discrepancy | 125,893 |
Short Trends | |
---|---|
Cover Days | 5 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Volume Discrepancy | 25,179 |
Average Short Volume | 1,371 |
Average Short Percentage | 14.66248% |
Read the Full Short Report https://squeezereport.com/short-reports/GNPX/
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
About Squeeze Report, Inc.
Squeeze Report, Inc. is a software company with proprietary predictive stock-trading algorithm software and two-dimensional artificial intelligence software that operates Squeeze Reports’ technology. The members of the Squeeze Report website (http://squeezereport.com) are allowed to utilize the proprietary predictive stock-trading algorithm among other financial related information.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: Disclaimer
This report is for the purposes of solicitation subscriptions for Squeeze Report. This featured company was chosen to be profiled by Squeeze Report Inc. after it completed due diligence on the company. Squeeze Report Inc. expects to generate new subscriber revenue, the amount of which is unknown at this time resulting from the distribution of this report. Squeeze Report did not receive any compensation for this report. Squeeze Report does not own any shares of Genprex, Inc. (NASDAQ: GNPX) and does not buy, sell, or trade any shares of Genprex, Inc. (NASDAQ: GNPX). This report does not provide a professional analysis of a Genprex, Inc. (NASDAQ: GNPX) financial position. Genprex, Inc. (NASDAQ: GNPX) financial position and all other information regarding the featured Company should be verified directly with Genprex, Inc. (NASDAQ: GNPX). Information about many publicly traded companies and other relevant information can be found at the Securities and Exchange Commission’s website at www.sec.gov. It is STRONGLY recommended that any investment in any security should especially in a penny stock like Genprex, Inc. (NASDAQ: GNPX) be made only after consulting with your professionally licensed investment advisor and still only after reviewing all publicly available information, including the financial statements of Genprex, Inc. (NASDAQ: GNPX). This report is not intended to be, nor should it be construed as, an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a of the purchase of Genprex, Inc. (NASDAQ: GNPX) securities. Squeeze Report presents information in this report believed to be reliable, but its accuracy cannot be guaranteed. Genprex, Inc. (NASDAQ: GNPX) is a penny stock and as such, is an EXTREMELY HIGH RISK INVESTMENT. An investor considering buying shares of Genprex, Inc. (NASDAQ: GNPX) should use only risk capital they can afford to lose completely. All past profits and track records attributed in this report are 100% hypothetical and paper profits. Track record examples are based entirely on hypothetical paper trades.